Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer

International Journal of Cancer

Volumn 126, Issue 7, 2010, Pages 1691-1701

  Tominaga, Toshiji ^a   Iwahashi, Makoto ^a   Takifuji, Katsunari ^a   Hotta, Tsukasa ^a   Yokoyama, Shozo ^a   Matsuda, Kenji ^a   Higashiguchi, Takashi ^a   Oku, Yoshimasa ^a   Nasu, Toru ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Chemosensitivity; Colorectal cancer; p53 mutation; p53 polymorphism

Indexed keywords

ARGININE; COLLAGEN GEL; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; ANTINEOPLASTIC AGENT; DNA; TP53 PROTEIN, HUMAN;

AGED; APOPTOSIS; ARTICLE; CELL COUNT; CHEMOSENSITIVITY; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; ADENOCARCINOMA; ADULT; CANCER STAGING; COLORECTAL TUMOR; DRUG EFFECT; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; COLORECTAL NEOPLASMS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77449111833     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24929     Document Type: Article

References (41)

1. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001;114:4139-40.
2. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
3. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
4. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
5. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinog 1995;12:124-31.
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
7. Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 2006;17:842-7.
8. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23:7518-28.
9. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and functionmutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003;100:8424-9.
10. Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005;25:6-17.
11. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
12. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
13. Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 2002;21:9-21.
14. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
15. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3: 387-402.
16. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-37.
17. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005;11:7328-33.
18. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, François E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.
19. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
20. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22: 229-37.
21. Sobin LH, Wittekind CL, eds. TNM classification of malignant tumors, 6th edition. New York: Wiley, 2002.
22. Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, Yasutomi M, Hanatani Y, Kotake K, et al. An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol 1997;11: 449-55.
23. Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B, Roessner A. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 2004;164:1233-41.
24. Hoffman RM, Connors KM, Meerson-Monosov AZ, Herrera H, Price JH. A general native-state method for determination of proliferation capacity of human normal and tumor tissues in vitro. Proc Natl Acad Sci USA 1989;86:2013-17.
25. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1:305-11.
26. Theodorakis P, Lomonosova E, Chinnadurai G. Critical requirement of BAX manifestation of apoptosis induced by multiple stimuli in human epithelial cancer cell lines. Cancer Res 2002;62:3373-6.
27. Nehls O, Okech T, Hsieh CJ, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Porschen R, Gregor M, Klump B. Low BAX protein expression correlates with disease-recurrence in preoperatively irradiated rectal carcinoma. Int J Radiat Oncol Biol Phys 2005;61:85-91.
28. Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B, Daniel PT. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer 2002;99:589-96.
29. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007;9:R34.
30. Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113:799-807.
31. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
32. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-4.
33. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr. Chemosensitivity linked to p73 function. Cancer. Cell. 2003;3:403-10.
34. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438-49.
35. Bénard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003;21:182-91.
36. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25:47-54.
37. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995;80: 293-9.
38. Zhan Q, Kontny U, Iglesias M, Alamo I, Jr, Yu K, Hollander MC, Woodworth CD, Fornace AJ, Jr, Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress. Oncogene 1999;18: 297-304.
39. Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, Manfredi JJ. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine Bax genes. Oncogene 2002;21:990-9.
40. Zhan Q, Bieszczad CK, Bae I, Fornace AJ, Jr, Craig RW. Induction of BCL-2 family member MCL1 as an early response to DNA damage. Oncogene 1997;14:1031-9.
41. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C, Vousden KH. p73 Induces apoptosis via. PUMA transactivation and. Bax mitochondrial translocation. J Biol Chem 2004;279: 8076-83.